Effectiveness of Anti-Psychotic in GPs Setting (Serenity)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00543088|
Recruitment Status : Completed
First Posted : October 12, 2007
Last Update Posted : April 23, 2009
|Condition or disease|
|Schizophrenia Bipolar Disorder|
|Study Type :||Observational|
|Enrollment :||250 participants|
|Official Title:||SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.|
|Study Start Date :||January 2007|
|Actual Study Completion Date :||June 2008|
- to evaluate the patient's functioning, by measuring the Quality of Life. Quality of Life will be assessed by the Q-LES-Q-16 (PRO).
- The clinical efficacy & tolerability of atypical antipsychotics as assessed by the Clinical Global Impression(CGI) & Patient Global Impression of Change(PGIC)scores.
- The wellbeing of the patients taking atypical antipsychotics as assessed by the Sheehan Disability Scale(SDS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00543088
Show 57 Study Locations
|Principal Investigator:||Pitchot W Pr||ULg|